Asset Details
Do you wish to reserve the book?
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation
Do you wish to request the book?
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation
2022
Overview
CD39/NTPDase1 has emerged as an important molecule that contributes to maintain inflammatory and coagulatory homeostasis. Various studies have hypothesized the possible role of CD39 in COVID-19 pathophysiology since no confirmatory data shed light in this regard. Therefore, we aimed to quantify CD39 expression on COVID-19 patients exploring its association with severity clinical parameters and ICU admission, while unraveling the role of purinergic signaling on thromboinflammation in COVID-19 patients. We selected a prospective cohort of patients hospitalized due to severe COVID-19 pneumonia (n=75), a historical cohort of Influenza A pneumonia patients (n=18) and sex/age-matched healthy controls (n=30). CD39 was overexpressed in COVID-19 patients’ plasma and immune cell subsets and related to hypoxemia. Plasma soluble form of CD39 (sCD39) was related to length of hospital stay and independently associated with intensive care unit admission (adjusted odds ratio 1.04, 95%CI 1.0-1.08, p=0.038), with a net reclassification index of 0.229 (0.118-0.287; p=0.036). COVID-19 patients showed extracellular accumulation of adenosine nucleotides (ATP and ADP), resulting in systemic inflammation and pro-coagulant state, as a consequence of purinergic pathway dysregulation. Interestingly, we found that COVID-19 plasma caused platelet activation, which was successfully blocked by the P2Y 12 receptor inhibitor, ticagrelor. Therefore, sCD39 is suggested as a promising biomarker for COVID-19 severity. As a conclusion, our study indicates that CD39 overexpression in COVID-19 patients could be indicating purinergic signaling dysregulation, which might be at the basis of COVID-19 thromboinflammation disorder.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adenosine Diphosphate - analysis
/ Adenosine Triphosphate - analysis
/ Blood Platelets - immunology
/ CD39
/ COVID-19
/ Critical Care - statistics & numerical data
/ Female
/ Humans
/ hypoxia
/ Influenza A virus - immunology
/ Influenza, Human - pathology
/ Male
/ Patients
/ Platelet Activation - immunology
/ Purinergic P2Y Receptor Antagonists - pharmacology
/ Receptors, Purinergic P2Y - metabolism
/ Signal Transduction - immunology
/ Thromboinflammation - immunology
